AVBP Q4 2025 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$36M

EPS (Diluted)

$-0.84

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$333M

Total Liabilities

$26M

Stockholders' Equity

$307M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$24M	-63.8%
Net Income	-$36M	-$21M	-72.3%